Helixon Biotechnology (Suzhou) Co., Ltd

The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are:
1. Does a single dose of HXN5003 in healthy participants impact the safety, tolerability and pharmacokinetic profiles?
2. Will immunogenicity of HXN5003 in healthy participants be altered? This study will be compared against a Placebo which contains the same inactive ingredients as those of HXN5003, but without the active ingredient.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants.
Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug).
Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

剂量探索阶段： 评估 HX15001 注射液多次给药在中重度活动性 UC 患者中的安全性和耐受性药代动力学特征和初步有效性。 剂量验证阶段： 主要目的 : 评估 在推荐剂量下，HX15001 注射液多次给药在中重度活动性 UC 患者中的初步有效性、安全性和PK特征。